Mindmed announces positive topline results from phase 2b trial of mm-120 in generalized anxiety disorder

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its phase 2b clinical trial of mm-120 (lysergide d-tartrate) in generalized anxiety disorder (gad). the trial met its primary endpoint, with mm-120 demonstrating statistically significant and clinically meaningful dose-depende.
MNMD Ratings Summary
MNMD Quant Ranking